Apellis Pharmaceuticals (APLS) that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer (PFE), during which he presided over the regulatory approval of more than 36 medicines and vaccines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $20 from $19 at Mizuho
- Apellis price target lowered to $18 from $20 at Wedbush
- Apellis price target lowered to $44 from $45 at Citi
- Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating
- Apellis price target raised to $48 from $45 at H.C. Wainwright